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INTRODUCTION
Type 1 and type 2 diabetes (T1D, T2D) are characterized by progressive β-cell dysfunction coupled with declining β-cell mass (1, 2) . At the time of T2D diagnosis, β-cell function is reduced by ~80% (3) and β-cell mass is reduced to 30-50% (4, 5) , while in T1D the β-cell deficit is more severe and averages 70-100% (6) . A dimorphic histology of long-duration T1D has been reported, with 70% of subjects showing only insulin-deficient islets and the remaining 30% showing numerous insulin-positive cells (7) (8) . Importantly, residual β-cell function has been demonstrated 30-40 years after the onset of T1D with ultrasensitive C-peptide assays (9) . Nevertheless, the loss of β-cells remains fundamental to the etiology of both forms of diabetes.
Preventing the loss and enhancing proliferation of β-cells is essential for maintaining long term metabolic control in T1D and T2D. However, the two most commonly prescribed antidiabetic drugs (metformin and sulfonylureas) are not effective in this regard (10-14) and sulfonylureas may even promote β-cell loss (15) . Synthetic long-acting glucagon-like peptide-1(GLP-1) receptor agonists (GLP-1 RA) exhibit glucoregulatory activities similar to native GLP-1, including glucosedependent enhancement of insulin secretion and inhibition of glucagon release, delayed gastric emptying and reduced food intake (16) (17) (18) (19) . Importantly, GLP-1 RAs also show proliferative effects, including enhanced β-cell replication, and reduced apoptosis (20) . Nevertheless, these in vivo cellular findings only have been described in rodents although in vitro evidence for these effects have been reported in human tissues (21) (22) (23) (24) (25) (26) . It is unknown whether GLP-1 RAs can stimulate βcell growth in vivo in humans, and the tissue sampling required to directly test these effects in a controlled setting is excessively invasive.
The baboon is recognized as an important preclinical model of human obesity, insulin resistance, and T2D that provides high translational value (27) (28) (29) (30) (31) . Compared to other species, the relative volume, distribution, and responses of islet cells are more consistent between human and nonhuman 5 primates (32) . In the present study, we generated a partial pancreatectomized model of diminished β-cell mass and islet cellular stress in baboons and tested the in vivo effects of chronic administration of the GLP-1 RA exenatide on: (i) islet cell replication, apoptosis, transdifferentiation (neogenesis), and ultrastructural integrity; (ii) αand β-cell secretory function; and (iii) insulin sensitivity. Our results provide the first direct in vivo evidence for enhanced βcell replication, decreased apoptosis, and reduced cellular stress following chronic GLP-1 RA administration in a non-human primate.
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RESULTS
Body Composition and Plasma Chemistries
Study population comprised twenty eight female nondiabetic baboons (Papio hamadryas Sp.).
Twenty-four animals underwent abdominal surgery with resection of the pancreatic tail [partial pancreatectomy (PPx)] and then were randomized to receive a chronic (13 weeks At the end of the study, serum exenatide levels were higher (758±162 pg/mL) in the exenatide group compared to the saline group (0.0 pg/mL). Body weight was significantly lower in the saline-treated group (16.7±0.7 vs.18.5±0.7 kg, p=0.01) at study end, whereas it did not change significantly in the exenatide group (17.2±0.6 vs. 18 .2±0.8 kg, p=0.08) (Suppl. Figure 1A) . Body composition analysis showed that lean mass was maintained in the exenatide group (15.2±0.5 vs. 15 .6±0.4 kg, p=0.24) but decreased in the saline-treated control baboons (16.1±0.5 vs. 15 .0±0.6 kg, p=0.03, Suppl. Figure   1B) . A significant decrease in fat mass was observed after treatment with both exenatide (1.54±0.45 vs. 0.93±0.20 kg, p≤0.05) and saline (1.27 ± 0.24 vs. 0.86 ± 0.21kg, p≤0.05, Suppl. Figure 1C) . The SHAM group did not undergo any significant changes in body composition or body weight over the study period. Food consumption was similar in the three groups, indicating that exenatide did not decrease energy intake (Suppl. Figure 1D) . No anorexia, vomiting, diarrhea or behavior changes were observed in animals treated with exenatide or saline. Clinical chemistries assessed before and after treatments did not show any significant change in the three study groups (Table 1) .
Specifically, there was no increase in plasma amylase after exenatide treatment. A decrease in Hb was observed in both saline and exenatide treated groups with no significant difference in Hb changes between the two study arms, suggesting that surgery and long-term catheterization may 7 have contributed to the decrease in Hb.
Exenatide improved β-cell function and insulin sensitivity, and induced β-cell rest
Plasma insulin and C-peptide concentrations during the 2-step hyperglycemic clamp are shown in Figure 1 A-F Figure 1A and B) , including during the arginine stimulation test (180-210 min). There were no significant changes in either the plasma insulin or C-peptide responses in the saline-treated (Figure 1 C, D) or SHAM (Figure 1E and F) groups. Similar results were obtained whether one used the 90-180, 0-90, or 60-90 minute time periods. No significant differences in the plasma glucose levels during the hyperglycemic clamp were observed between the three study groups (Suppl. Figure 2A) . Plasma glucagon concentrations were not changed after treatment in any of the groups (Suppl. Figure 2B) . The AUC for plasma insulin and C-peptide concentrations (0-210 min) were significantly reduced by exenatide treatment while no significant changes were observed in saline-treated and SHAM groups (Figure 2A and B) . 
Exenatide promoted islet cell replication and differentiation, and reduced apoptosis.
Of particular note, in baboons who served as anatomic controls islet β-cell, and α-cell volumes in the head-body were significantly reduced (by 25-33%), compared to the tail, while δ-cell volumes were not different between regions ( Figure 3A) . In baboons who received saline for 13
weeks, at study end islet volume in the head-body region was significantly reduced compared to the tail region ( Figure 3B) . In exenatide treated-baboons, at study end islet volume in the head-body region was unchanged compared to the tail region ( Figure 3B ) and, importantly, it was higher than that in the head-body region of saline treated-animals (p=0.02, Figure 3B ). Notably, since islet volume in anatomic controls and saline-treated baboons is normally lower in the head-body vs tail, an "unchanged" islet volume in exenatide group indicates a growth promoting effect of exenatide on islet volume. In saline-treated baboons, at study end β-cell volume in the head-body region also was significantly reduced compared to the tail region (3.1±0.8% vs 5.5±1.6%, p=0.003, Figure 3C ). In marked contrast, at study end β-cell volume in the head-body of pancreata from exenatide-treated animals was not significantly different from that in the tail before treatment (5.6±2.6% vs. 4.7±1.6%, Figure 3C ) and it was significantly increased compared to the β-cell volume in the head-body region of the anatomic control group (4.7±1.6% vs 3.2±1.2%, p=0.01) and of saline-treated baboons Figure 4A ). Using immunofluorescence, the replication marker Ki67 co-localized with insulin-positive cells, confirming that β-cells were among the islet cells undergoing replication with exenatide treatment (Suppl Figure 7) . Further, we observed that the replication marker Ki67 co-localized with glucagon-positive cells in exenatide-treated baboons (Suppl. Figure 8) , indicating that treatment with exenatide also stimulated α-cells replication. As compared to baseline, the percentage of M30 positive cells was not significantly different at study end in the exenatide group, but was significantly increased in the saline-treated control group ( Figure  4B ), indicating decreased apoptosis in the islets of baboons who received exenatide compared with saline. After exenatide treatment, the percentage of islet cells staining positive for the transdifferentiation marker c-Kit was significantly increased compared to baseline (p=0.01), and it was significantly higher than in saline-treated baboons (p=0.01) (Figure 4C , Suppl. Figure 6C) .
Immunofluorescence demonstrated the presence of cells staining positively for both c-Kit and insulin (Suppl Fig. 9 ), documenting that islet β-cells were among the cells undergoing trans-differentiation in the exenatide group. Co-localization of insulin and somatostatin was not observed before or after treatment with either exenatide or saline (Suppl. Figure 10 ).
Exenatide resulted in islet cell ultrastructural changes consistent with protection from cellular stress and secretory dysfunction
Electron microscopy was undertaken to visualize islet cell ultrastructure and β-cell secretory granule morphology and composition before and after treatment in the exenatide and saline groups Immuno-gold labeling with electron microscopy provided further support for normal β-cell secretory function following exenatide treatment (Figure 7) . The number of proinsulin labelled granules was greater in the saline treated group compared to the exenatide-treated baboons (Figure   7 A-D). Insulin appearance inside the granules remained unchanged from basal to the end of study in the exenatide group (Figure 7 C,D) . Consistent with these findings, the plasma proinsulin concentration during the hyperglycemic clamp was significantly lower after exenatide treatment (Suppl. Figure 12 ).
β-cells in the saline-treated group had morphological changes consistent with endoplasmic reticulum and mitochondrial stress (Figure 8) . Specifically, in the saline-treated group mitochondrial cristae were disordered and endoplasmic reticulum and Golgi membranes showed features of degeneration (Figure 8 B) ; such changes in mitochondrial, endoplasmic reticulum, and
Golgi structure were not found in the exenatide-treated group (Figure 8 D) . Collectively, the electron microscopic findings are consistent with a phenotype of whole islet and β-cell stress and are consistent with the functional defect in insulin secretion induced by PPx. In contrast, the islets of exenatide-treated animals were protected from these structural and functional abnormalities.
DISCUSSION
GLP-1 RAs improve glucose control through several and, as of yet, not completely understood mechanisms, including glucose-dependent enhancement of insulin secretion and inhibition of glucagon release (16) (17) (18) (19) 33) .
We report the first direct evidence in a non-rodent species for enhanced β-cell replication and decreased β-cell apoptosis and cellular stress following chronic exenatide administration.
Since the genetic background of the baboon closely resembles that of man, this observation raises the possibility that GLP-1 RA can stimulate β-cell proliferation in humans if a sufficiently high plasma GLP-1 RA concentration can be achieved. We also observed an increase in whole body insulin sensitivity after exenatide treatment in association with a compensatory decrease in insulin secretion. Notably, the disposition index increased following exenatide treatment, indicating that intrinsic β-cell secretory function was enhanced by exenatide treatment in face of increased insulin sensitivity. Further, the percent increase in the disposition index was greater than the percent increase in beta cell volume (an indirect measure of β-cell mass), indicating that exenatide exerts independent actions both to stimulate β-cell proliferation and to augment β-cell function.
The partially pancreatectomized baboon model was designed, based upon the partially might be possible to stimulate β-cell proliferation and increase β-cell mass.
After exenatide treatment we also detected a significant number of cells which stained 14 positive for the stem cell marker c-Kit, which has been shown to be involved in islet development and β-cell proliferation, maturation and survival (42, 43) . c-Kit positive cells were demonstrated both in islets and ducts and a fraction of them co-stained for insulin. Conversely, c-Kit positive cells were absent in all groups before treatment and were absent after treatment in the saline-treated group. These findings are in agreement with those described in a previously published study, in which we observed c-Kit positive cells co-expressing insulin in pancreatic ducts of baboons treated with exenatide (31) . However, the absence of cells co-staining for insulin and somatostatin, as observed in states of stimulated β-cell neogenesis, suggests that increased replication, rather than neogenesis, accounts for exenatide-stimulated β-cell growth in the present study.
Safety concerns have emerged about the potential proliferative effects of exenatide and other GLP1 RAs, although causal evidence for a link between exenatide and pancreatic cancer is lacking. We recently reported that chronic infusion of exenatide for 14 weeks did not induce pancreatitis, parenchymal or periductal inflammatory cell accumulation, ductal hyperplasia, or dysplastic lesions/pancreatic intraepithelial neoplasia in baboons (31) . Similarly, in the present study no inflammatory or neoplastic changes were observed and there was no increase in plasma amylase concentration in exenatide-treated baboons. Importantly, although serum exenatide levels were markedly increased at the end of the study, no side effects, including vomiting and anorexia, were observed in exenatide-treated animals.
During the repeat hyperglycemic clamp at study end, exenatide-treated baboons had lower insulin secretory responses to both glucose and L-arginine compared to the basal, pretreatment hyperglycemic clamp study. The decrease in insulin secretion most likely was attributable to the concomitant increase in insulin sensitivity. However, when insulin secretion is related to the degree of insulin resistance (disposition index), exenatide treatment resulted in a significant, almost 2-fold increase in β-cell function. This observation is consistent with prior studies with exenatide in humans (44) . Recent studies by us (45, 46) support an insulin sensitizing effect of exenatide in both muscle and liver. Accordingly, we have reported that GLP-1 receptor protein is expressed in the skeletal muscle and liver of baboons, and it also is present in human skeletal muscle (45) . Other studies also suggest that exenatide improves insulin sensitivity, independent of changes in body weight (47) (48) (49) . In the present study, treatment with exenatide did not significantly change total body weight or lean body mass. Although total body fat mass declined in exenatide-treated baboons, a similar decrease was observed in saline-treated animals in whom insulin sensitivity did not increase. Since the suppression of plasma glucagon during the hyperglycemic clamp was similar in all groups, differences in plasma glucagon concentration cannot explain the increase in insulin sensitivity in the exenatide-treated group. Therefore, the increase in insulin sensitivity observed after exenatide treatment most likely was due to a direct insulin sensitizing effect. Levels of p-Akt ser 473 increased significantly in skeletal muscle of exenatide-treated baboons compared to baseline and to saline-treated controls and could, at least in part, play a role in the increase in insulin sensitivity. No significant changes were observed in any other mediators of insulin action in muscle. In liver, amongst the measured mediators of insulin action, the only change that we found was a decrease in ERK phosphorylation, which is not a typical mediator of insulin's effect on glucose metabolism.
Therefore, it is unlikely that the insulin sensitizing effect of exenatide can be attributed to an increase in insulin signal transduction and suggests that exenatide may exert its insulin sensitizing effect on post-receptor post-signaling intracellular pathway(s). Consistent with this, we recently demonstrated that exenatide activates glucose transport by an AMP-activated protein kinase (AMPK) dependent mechanism in vitro (45) . (49) and renders β-cells less vulnerable to cytotoxic insults (50-52).
Research trials and clinical practice have shown that treatment with exenatide causes body weight and fat mass reduction (16) (17) (18) (19) secondary to decreased energy intake (53) . However, it has been hypothesized that GLP-1 RAs also might be involved in the regulation of energy metabolism (54) (55) (56) . Although we found a significant decrease in fat mass in exenatide-treated baboons, a similar decrease in fat mas was observed in the saline-treated groups at study end. Lean mass and body weight were slightly decreased after saline treatment; similarly, a small but insignificant decrease in lean mass and body weight was found in the exenatide group. Overall, these variations in body composition are modest in both study groups and may be the consequence of surgery and long-term catheterization rather than an effect of exenatide or saline treatment. Food intake did not differ between exenatide-treated and saline-treated baboons, indicating that the dose of exenatide used in the present study did not alter energy intake.
A number of limitations should be considered when interpreting our results. First, we studied only female baboons. Although this methodological approach, which commonly is used in animal-based studies makes the results more homogeneous, whether our results can be generalized to male primates needs to be established. Second, we did not measure energy expenditure; therefore, we cannot firmly establish that exenatide does not affect energy expenditure. However, the observation that body weight and food consumption were stable during the study period in the two experimental groups does not support a significant change in energy expenditure. We did not observe significant differences in fasting plasma glucose and HbA1c levels between exenatide, saline or SHAM groups, indicating that baboons in the three study groups did not develop diabetes. This most likely is explained by the surgical PPx which only removed a relatively small portion of pancreas (about 1/3 of pancreas) which was followed by a compensatory increase in insulin secretion by the remaining pancreas. However, we have no data regarding post-prandial glucose levels. Although we cannot exclude the possibility that there were differences in postprandial glucose levels between saline-and exenatide-treated animals, we think that this is unlikely since the HbA1c, as well as the fasting glucose, was similar in the two experimental groups.
In conclusion, chronic intravenous exenatide administration causes: (i) a ~2-fold increase in This study provides solid grounds for further studies aimed at exploring GLP1 RAs capability to preserve β-cell mass in patients with diabetes and in subjects at high risk of developing diabetes, and for investigate in more detail the pharmacodynamics of anti-diabetic drugs including GLP1 RAs in baboons.
METHODS
Study Population
Twenty Prior to treatment baboons underwent a body composition analysis and long-term catheterization for blood collection and drug infusion by placing heparin-coated polyurethane catheters in the internal jugular vein and carotid artery. Catheters were routed subcutaneously to the mid-scapular region where they were connected to the tether jacket chronic infusion system (31, 57) . Three days after catheterization (i.e., before abdominal surgery), a 2-step hyperglycemic clamp with arginine stimulation was performed. Within 3-5 days after the hyperglycemic clamp, abdominal surgery was performed as described below and total parenteral nutrition was started. After a 96-hour recovery period, baboons were fed again with standard chow and were chronically infused (24 hours/day) for 13 weeks with either normal saline or exenatide (Byetta, Amylin Pharmaceuticals, San Diego, CA) diluted in normal saline at the rate of 0.014 µg/kg.hour, as previously described (31) . At the end of the 13 week treatment period, following a 72-hour washout period, baboons underwent a second body composition analysis and a 2-step hyperglycemic clamp with arginine stimulation. Baboons were then euthanized and the whole pancreas from SHAM group and the remnant pancreas (head-body) from the other two groups was harvested.
An additional group of sixteen baboons (8 males, 8 females) was studied as controls for pancreatic anatomy. Their whole pancreas was removed at necropsy to determine the difference in islet histology and islet cell volumes in the tail versus head-body of the pancreas.
Body Composition Analysis
Baboons underwent a dual-energy X-ray absorptiometry (DXA) scan to determine fatfree mass, fat mass, percent body fat and bone mineral content. Scanning was performed on ketamine-sedated animals and data were analyzed using the software Encore2007 (GE Healthcare, Madison, WI).
Hyperglycemic Clamp
After a 10-12 hour overnight fast, baboons were sedated and intubated endotracheally under direct laryngoscopic visualization. Deep anesthesia was induced using a mix of oxygen and inhaled isofluorane (1.5% V/V). After 60-90 minutes to allow animal stabilization, a 2-step hyperglycemic clamp with arginine stimulation was performed (58) . From 0-90 minutes the plasma glucose concentration was raised by 100 mg/dl (i.e. from ~90 to 190 mg/dl) and from 90-180 minutes the plasma glucose concentration was raised by an additional 100 mg/dl (i.e. from ~190 to 290 mg/dl). At 180 minutes animals received a bolus (0.5 gram/kg of body weight) injection of arginine (10% arginine hydrochloride, Hospira, Lake-Forest, IL) and the animals were followed for an additional 30 minutes. Plasma glucose concentration was measured every 2 minutes 20 from 0-10, 90-100, and 180-190 minutes and every 5-10 minutes from 10-90, 100-180, and 190-220 minutes. Glucose was measured by using a glucose analyzer (GM9 Glucose Analyzer, Analox Instruments, Lunenburg, MA) and insulin, glucagon and C-peptide by radioimmunoassay (27) .
The following parameters were computed: (i) AUC for insulin and C-peptide concentration (0- 
Partial Pancreatectomy
PPx was performed under general anesthesia with isofluorane 1.5% V/V as previously described (31) by making an incision on the mesoduodenum or omentum on each side of the pancreas to mark the portion to be removed. The pancreas then was ligated immediately proximal to the marks and the distal part (tail), accounting for ~30% of the pancreas, was removed and collected for histologic analysis prior to the start of treatment. Previous studies in primates and humans have shown that more than 50% of the pancreas mass must be excised in order to stimulate compensatory β-cell regeneration (62, 63) . SHAM-operate baboons underwent a sham surgical procedure similar to that in the other two study groups without undergoing PPx.
Following the surgery, i.v. parenteral nutrition with 5% glucose solution, potassium, and amino acids was provided during a recovery period of 4 days along with antibiotics and analgesics. The perioperative/postoperative mortality was 0%. Solid food was again introduced after the recovery period and baboons were housed inside individual cages while on tether for treatment (31) .
Western Blots for Insulin Signaling
Skeletal muscle and liver samples were obtained following the second 2-step hyperglycemic clamp (i.e., after 13 weeks of exenatide or saline infusion) and frozen in liquid nitrogen. Western blot experiments were performed as described previously (64) measurements was estimated twice in 5 specimens with a coefficient of variation less than 5%. Each field of the slide was randomly selected using the CAST meander sampling. On average, we analyzed 125 ± 46 islets per animal per group on each slide, before and after treatment. Pancreas weight at baseline was 6.8±1.8 vs 6.4±1.8g for the exenatide and saline group, respectively (p=0.788); at the end of the study, pancreas weight was 12.8±2.4 vs 14.5±3.9g (p=0.271), respectively. Data obtained from CAST were expressed as % of total pancreas as previously described (30) . For the evaluation of secretory mature granules and pro-granules of β-cells, 4 cells for each group (pre-and post-saline treated, pre-and post-exenatide treated) were evaluated. The immunogold labellings were evaluated with a semi-quantitative method.
Immunofluorescence Staining
3-µm thick pancreatic sections were fixed and immunostained as previously described (31, 65) . The following antibodies were used: anti-insulin guinea pig monoclonal (DAKO), anti-c-kit mouse monoclonal (Cell Signaling), anti-ki67 rabbit polyclonal antibody (Cell Signaling) and
anti-somatostatin mouse monoclonal antibody (DAKO). Islets were imaged using a Bio-Rad MRC 1024 confocal laser scanning microscope (BIORAD). Confocal images were acquired sequentially, using the LaserSharp2000 software with a low iris diameter (66) .
Controls for Regional Differences in Islet Cell Volume
It is well established that there are significant differences between the number of islets in the tail versus head-body of the pancreas. In order to ensure accurate comparison of islet cell volumes before and after PPX (tail vs. head-body), we measured α, β, and δ-cell volumes in both the tail and head-body regions from whole, intact pancreases obtained from a representative sample of 16 randomly selected baboons who did not participate in the study.
Statistical Analysis
Data for continuous variables are given as the mean ± SD. Given the small sample size (12 baboons in saline group, 12 in exenatide group and 4 animals in SHAM group, n=28), nonparametric tests were carried out to analyze the data.
Differences in clinical data amongst the study groups were evaluated by using a general linear model with post hoc Fisher's least significant difference correction for pairwise comparisons.
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To compare changes between baseline and end of study parameters in each study group we used Wilcoxon test. Statistical analyses were performed by using Stata/SE Version 11.2 (Stata Corp LP, College Station, TX). We considered a two-sided P value ≤0.05 statistically significant. 
Study approval
